Kazuya Tokumura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuya Tokumura has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Eiichi Hinoi
Department of Bioactive Molecules, Pharmacology, Gifu Pharmaceutical University, Gifu, Japan
22 shared publications - Akane Suzuki
Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University, Gifu, Japan
20 shared publications - Akane Tomizawa
Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University, Gifu, Japan
20 shared publications - Jiajun Lyu
Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University, Gifu, Japan
20 shared publications - Kazuya Fukasawa
Lab. Pharmacol., Dept. Bioactive Molecules, Gifu Pharmaceutical Univ
20 shared publications - Ryoma Osumi
Laboratory of Pharmacology, Department of Bioactive Molecules, Gifu Pharmaceutical University, Gifu, Japan
20 shared publications
Latest Publications
- Open Access
- 29 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 574
PDK1-dependent metabolic reprogramming regulates stemness and tumorigenicity of osteosarcoma stem cells through ATF3
Osteosarcoma stem cells (OSCs) are characterized by their self-renewal and multilineage differentiation abilities, contributing to osteosarcoma malignancy. The Warburg effect describes cancer cells’ preference for glycolysis over mitochondrial oxidative phosphorylation (OXPHOS) for energy production. Unlike differentiated cancer cells, cancer stem cells exhibit unique and diverse metabolic properties depending on the context. This study investigated the metabolic reliance of OSCs and related genes through in silico analyses of clinical osteosarcoma specimens and in vitro and in vivo genetic and pharmacological analyses. Glycolysis and OXPHOS pathways were more active in OSCs than in non-OSCs at single-cell resolution. Pyruvate dehydrogenase kinase 1 (PDK1), a key enzyme balancing glycolysis and OXPHOS, was upregulated in OSCs and correlated with poor prognosis in patients with osteosarcoma. Genetic inhibition of PDK1 via RNA interference reduced OSC stemness, glycolysis, and heterotopic tumor formation. Pharmacological inhibition of PDK1 mirrored these genetic effects and repressed orthotopic tumor burden and pulmonary metastasis. Activating transcription factor 3 (ATF3) was identified through screening as a downstream factor of PDK1-regulated OSC properties. ATF3 overexpression reversed the stemness reduction caused by PDK1 deficiency through, at least in part, activating the TGF-β/Smad pathway without affecting the metabolic balance. ATF3 expression, glycolysis, and stemness were significantly induced by wild-type PDK1 overexpression but not by a kinase-dead PDK1 mutant in OSCs. Pharmacological inhibition of glycolysis counteracted the upregulation of ATF3 expression and increased stemness in OSCs by PDK1 overexpression. These findings indicate that PDK1 fine-tunes metabolic balance to govern OSC stemness and tumorigenicity through, at least in part, modulating ATF3/TGF-β/Smad pathway, suggesting a potential therapeutic approach for targeting OSCs in osteosarcoma.
- 29 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 574
Open AccessPDK1-dependent metabolic reprogramming regulates stemness and tumorigenicity of osteosarcoma stem cells through ATF3
Osteosarcoma stem cells (OSCs) are characterized by their self-renewal and multilineage differentiation abilities, contributing to osteosarcoma malignancy. The Warburg effect describes cancer cells’ preference for glycolysis over mitochondrial oxidative phosphorylation (OXPHOS) for energy production. Unlike differentiated cancer cells, cancer stem cells exhibit unique and diverse metabolic properties depending on the context. This study investigated the metabolic reliance of OSCs and related genes through in silico analyses of clinical osteosarcoma specimens and in vitro and in vivo genetic and pharmacological analyses. Glycolysis and OXPHOS pathways were more active in OSCs than in non-OSCs at single-cell resolution. Pyruvate dehydrogenase kinase 1 (PDK1), a key enzyme balancing glycolysis and OXPHOS, was upregulated in OSCs and correlated with poor prognosis in patients with osteosarcoma. Genetic inhibition of PDK1 via RNA interference reduced OSC stemness, glycolysis, and heterotopic tumor formation. Pharmacological inhibition of PDK1 mirrored these genetic effects and repressed orthotopic tumor burden and pulmonary metastasis. Activating transcription factor 3 (ATF3) was identified through screening as a downstream factor of PDK1-regulated OSC properties. ATF3 overexpression reversed the stemness reduction caused by PDK1 deficiency through, at least in part, activating the TGF-β/Smad pathway without affecting the metabolic balance. ATF3 expression, glycolysis, and stemness were significantly induced by wild-type PDK1 overexpression but not by a kinase-dead PDK1 mutant in OSCs. Pharmacological inhibition of glycolysis counteracted the upregulation of ATF3 expression and increased stemness in OSCs by PDK1 overexpression. These findings indicate that PDK1 fine-tunes metabolic balance to govern OSC stemness and tumorigenicity through, at least in part, modulating ATF3/TGF-β/Smad pathway, suggesting a potential therapeutic approach for targeting OSCs in osteosarcoma.
- Open Access
- 18 December 2024
- Published by Springer Nature in Research Square
PDK1-dependent metabolic reprogramming regulates stemness and tumorigenicity of osteosarcoma stem cells through ATF3
Osteosarcoma stem cells (OSCs) are characterized by their self-renewal and multilineage differentiation abilities, contributing to osteosarcoma (OS) malignancy. The Warburg effect describes cancer cells’ preference for glycolysis over mitochondrial oxidative phosphorylation (OXPHOS) for energy production. Unlike differentiated cancer cells, cancer stem cells exhibit unique and diverse metabolic properties depending on the context. This study investigated the metabolic reliance of OSCs and related genes through in silico analyses of clinical OS specimens and in vitro and in vivo genetic and pharmacological analyses. Glycolysis and OXPHOS pathways were more active in OSCs than in non-OSCs at single-cell resolution. Pyruvate dehydrogenase kinase 1 (PDK1), a key enzyme balancing glycolysis and OXPHOS, was upregulated in OSCs and correlated with poor prognosis in patients with OS. Genetic inhibition of PDK1 via RNA interference reduced OSC stemness, tumorigenicity, and glycolysis. Pharmacological inhibition of PDK1 mirrored these genetic effects. Activating transcription factor 3 (ATF3) was identified through screening as a downstream factor of PDK1-regulated OSC properties. Silencing ATF3 reduced OSC stemness, while ATF3 overexpression reversed the stemness reduction caused by PDK1 deficiency. ATF3 expression, glycolysis, and stemness were significantly induced by wild-type PDK1 overexpression but not by a kinase-dead PDK1 mutant in OSCs. Pharmacological inhibition of glycolysis counteracted the upregulation of ATF3 expression and increased stemness in OSCs by PDK1 overexpression. These findings indicate that PDK1 fine-tunes metabolic balance to govern OSC stemness and tumorigenicity through ATF3, suggesting a potential therapeutic approach for targeting OSCs in OS.
- 18 December 2024
- Published by Springer Nature in Research Square
Open AccessPDK1-dependent metabolic reprogramming regulates stemness and tumorigenicity of osteosarcoma stem cells through ATF3
Osteosarcoma stem cells (OSCs) are characterized by their self-renewal and multilineage differentiation abilities, contributing to osteosarcoma (OS) malignancy. The Warburg effect describes cancer cells’ preference for glycolysis over mitochondrial oxidative phosphorylation (OXPHOS) for energy production. Unlike differentiated cancer cells, cancer stem cells exhibit unique and diverse metabolic properties depending on the context. This study investigated the metabolic reliance of OSCs and related genes through in silico analyses of clinical OS specimens and in vitro and in vivo genetic and pharmacological analyses. Glycolysis and OXPHOS pathways were more active in OSCs than in non-OSCs at single-cell resolution. Pyruvate dehydrogenase kinase 1 (PDK1), a key enzyme balancing glycolysis and OXPHOS, was upregulated in OSCs and correlated with poor prognosis in patients with OS. Genetic inhibition of PDK1 via RNA interference reduced OSC stemness, tumorigenicity, and glycolysis. Pharmacological inhibition of PDK1 mirrored these genetic effects. Activating transcription factor 3 (ATF3) was identified through screening as a downstream factor of PDK1-regulated OSC properties. Silencing ATF3 reduced OSC stemness, while ATF3 overexpression reversed the stemness reduction caused by PDK1 deficiency. ATF3 expression, glycolysis, and stemness were significantly induced by wild-type PDK1 overexpression but not by a kinase-dead PDK1 mutant in OSCs. Pharmacological inhibition of glycolysis counteracted the upregulation of ATF3 expression and increased stemness in OSCs by PDK1 overexpression. These findings indicate that PDK1 fine-tunes metabolic balance to govern OSC stemness and tumorigenicity through ATF3, suggesting a potential therapeutic approach for targeting OSCs in OS.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table ST1 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table ST1 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells